Clinical Trials

Phase I Studies
Brilaroxazine (RP5063) phase 1B in stable schizophrenia patients — Completed
Brilaroxazine (RP5063) phase 1A study in healthy subjects — Completed

Phase II Studies
Randomized, double-blind, placebo-controlled, multicenter (USA, EU, Asia) phase II study to assess the safety and efficacy of brilaroxazine (RP5063) in subjects with acute exacerbation of schizophrenia or schizoaffective disorder — Completed

Phase III Studies
Randomized, double-blind, placebo-controlled, multicenter (USA, EU, Asia) phase III study to assess the safety and efficacy of brilaroxazine (RP5063) in subjects with acute exacerbation of schizophrenia – Ongoing

Open-label, multicenter (USA, EU, Asia) phase III study to assess the safety and tolerability of brilaroxazine (RP5063) in subjects with stable schizophrenia – Ongoing